Literature DB >> 26149073

Sequence analysis of genes mediating extended-spectrum beta-lactamase (ESBL) production in isolates of Enterobacteriaceae in a Lagos Teaching Hospital, Nigeria.

Muhabat Adeola Raji1,2, Wafaa Jamal3, Omoh Ojemeh4, Vincent Olubunmi Rotimi5.   

Abstract

BACKGROUND: Extended-spectrum β-lactamases (ESBLs) in Gram-negative organisms is now a major concern in Enterobacteriaceae worldwide. This study determined a point-prevalence and genetic profiles of ESBL-producing isolates among members of the family Enterobacteriaceae in Lagos State University Teaching Hospital Ikeja, Nigeria.
METHODS: Consecutive non-repetitive invasive multidrug-resistant isolates of the family Enterobacteriaceae obtained over a period of 1 month (October 2011) were studied. The isolates were identified using VITEK-2/VITEK MS Systems. Susceptibility testing was performed using E test technique; results were interpreted according to the criteria recommended by the Clinical and Laboratory Standards Institute (CLSI, 2012). ESBL production was detected by E test ESBL method and confirmed by polymerase chain reaction (PCR).
RESULTS: During the one-month study period, 38 isolates with ESBL phenotypic characteristics were identified and confirmed by PCR. Of these, 21 (55.3 %) were E. coli, 12 (31.6 %) K. pneumoniae, 3 (7.9 %) Proteus spp., 1 (2.6 %) each M. morganii and C. freundii. Thirty (79 %) harbored bla CTX-M genes. Sequence analysis revealed that they were all bla CTX-M-15 genes. Twenty-nine (96.7 %) of these, also harbored bla TEM genes simultaneously. All the CTX-M-15-producing isolates carried insertion sequence bla ISEcP1 upstream of bla CTX-M-15 genes. The E. coli isolates were genetically heterogeneous, while the K. pneumoniae had 98 % homology.
CONCLUSIONS: Our point-prevalence surveillance study revealed a high prevalence of Enterobacteriaceae isolates harboring bla CTX-M-15 in the Hospital. Urgent implementation of antibiotic stewardship and other preventive strategies are necessary at this time in our hospital.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26149073      PMCID: PMC4493960          DOI: 10.1186/s12879-015-1005-x

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Gram-negative organisms belonging to the family Enterobacteriacae commonly produce beta-lactamases, which confer resistance to most penicillins but not to expanded-spectrum cephalosporins. The genes encoding these beta-lactamases are plasmid-borne, and belong to the TEM-1, TEM-2, and SHV-1 types [1]. Infections caused by members of the family Enterobacteriaceae are treated with cephalosporins, particularly the third-and fourth-generation cephalosporins. However, resistance to these drugs has emerged throughout the world with widespread of resistant strains. By the middle of the 80s, resistance to the expanded-spectrum cephalosporin became evident and various studies have shown that the resistance was mediated by structural mutation in the older enzymes [1, 2]. In Enterobacteriaceae, resistance to cephalosporin is commonly due to production of extended-spectrum β-lactamases (ESBLs). The emergence of ESBLs in Gram-negative organisms is now a major concern worldwide [1], and the presence of these enzymes is among the most important resistance determinants to have emerged in Enterobacteriaceae [3-7]. Most ESBLs are derivatives of TEM and SHV β-lactamase families. Other groups such as PER and CTX-M types have been described [8, 9]. In addition, other β-lactamases, including those belonging to Ambler class B (metallo-β-lactamase), class A (e.g. KPC) or class D (OXA-48), capable of hydrolyzing carbapenems have emerged [10-12]. The literature is awash with evidence of global dissemination of CTX-M type ESBL of pandemic proportion [9, 13, 14]. The production of this enzyme is mediated by the blaCTX-M gene, which confers resistance to the third-generation cephalosporins particularly in Escherichia coli and Klebsiella spp. [15]. Several phenotypic and genotypic studies have documented the emergence of CTX-M-type extended-spectrum β-lactamases as well as the genes encoding their production in Enterobacteriaceae, in Nigeria. However, most of these studies have been on randomly selected E. coli and K. pneumoniae [16-19] and Salmonella enterica serovar Typhi [20] and thus the true prevalence of CTX-M in most parts of the country is unknown. In our hospital, cephalosporins are first line antibiotics used in the treatment of Gram-negative sepsis and other infective conditions. A previous study conducted earlier in the same hospital demonstrated high resistance rates among clinically significant species of the family Enterobacteriaceae against the cephalosporins and other β-lactam antibiotics [21]. With such high resistance rates, it is conceivable that CTX-M would also be the dominant ESBL type responsible for this high level of resistance in our hospital. This study was undertaken to investigate a point-prevalence and genetic profiles of ESBL-producing isolates among members of the family Enterobacteriaceae causing infections in patients on admission in a tertiary hospital in Lagos.

Methods

Bacterial isolates and setting

Thirty-eight consecutive isolates of multidrug-resistant invasive species of the family Enterobacteriaceae were obtained over a period of one month (October 2011), during routine laboratory investigation, from in-patients at the Lagos State University Teaching Hospital (LASUTH) located in Ikeja, a suburban part of Lagos. The hospital serves as a referral center for about 6 million Lagosians. It has one adult Intensive Care Unit (ICU), 1 Critical Care Unit (CCU), a dialysis unit and an oncology unit. The age, sex, nationality, previous hospital admissions, and documented travel history were all carefully noted. Duplicate isolates were omitted from the study. The bacterial isolates were identified by VITEK-2 system (bioMérieux, Hazelwood, MO, USA). In addition, when necessary, further confirmation was carried out with VITEK MS, a matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) system (bioMerieux, Marcy-l’Etoile, France).

Susceptibility testing

Susceptibility testing of the isolates was performed by determining the minimum inhibitory concentrations (MICs) of amikacin, amoxicillin-clavulanic acid, cefepime, cefotaxime, cefoxitin, ceftazidime, ciprofloxacin, colistin, ertapenem, imipenem, gentamicin, meropenem, piperacillin-tazobactam, and tigecycline on Mueller-Hinton agar plates using E test (bioMerieux) technique. A quality control strain, Escherichia coli ATCC 25922 was included in each run. The results were interpreted according to the break-points and criteria recommended by the Clinical and Laboratory Standards Institute (CLSI, 2012) [22].

Confirmation of ESBL

All the ESBL-producing isolates were phenotypically detected by E test ESBL method using cefotaxime (CT)/cefotaxime combined with clavulanic acid (CTL) and ceftazidime (TZ)/ceftazidime combined with clavulanic acid (TZL) (bioMerieux) and were confirmed by polymerase chain reaction (PCR). In-house ESBL-producing E. coli strain K31 [23] and ESBL-negative strain were included in the test runs as positive and negative controls, respectively.

PCR amplification and sequencing

PCR assays were carried out with a series of primers to detect the following genes mediating blaSHV, blaTEM, blaCMY-6, blaCMY-4, and blaCTX-M [24]. PCR products were sequenced with a 3130xl Genetic Analyzer (Applied Biosystems, Hitachi High-Technologies Corporation, Tokyo, Japan). Sequences were compared and aligned with reference sequences available in the GenBank.

Detection of insertion sequence, ISEcp1

The genetic organization of the blaIS was investigated by sequencing this short segment using the following primers: ISEcp1A (5’-GCA GGT CTT TTT CTG CTC C-3’) and ISEcp1B (5’- ATT TCC GCA GCA GCA CCG TTT GC- 3’) [25].

Genotyping of isolates

Fifteen randomly selected strains of the blaCTX-M-15-positive isolates (9 E. coli and 6 K. pneumoniae) were investigated for genetic relatedness using pulsed-field gel electrophoresis (PFGE) with Xba1 digestion of the genomic DNA separated by electrophoresis in 1.2 % agarose gel [26] and the strains compared by differences in number and mobility of the bands.

Results

During this one month study, a total of 73 isolates belonging to the family Enterobacteriaceae were studied. Of these, 38 (52.1 %) were ESBL-producing isolates, 21 (55.3 %) of which were E. coli, 12 (31.6 %) K. pneumoniae, 3 (7.9 %) Proteus spp., 1 each (2.6 %) M. morganii and Citrobacter freundii. They were isolated from urine (24), wound swabs (8), blood culture (3) and respiratory secretions (3). These specimens were obtained from infected in-patients who were ethnic Nigerians, predominantly Yorubas. Their ages ranged from 6 – 89 years (mean 59.2 years); 20 (52.6 %) were males and 18 (47.4 %) females with a male-to-female ratio of 1.1:1.

Prevalence of blaCTX-M ESBL-positive Enterobacteriaceae

The ESBL-producing E. coli and K. pneumoniae were multidrug-resistant isolates (MDR) showing resistance to five or more antibiotics (Table 1). The number of MDR P. mirabilis, M. morganii and C. freundii isolates was too small for any analysis.
Table 1

Antibiotic susceptibility profiles of the bla CTX-M ESBL-positive E. coli and K. pneumoniae.

AntibioticsMIC (μg/ml) for the bla CTX-M-positive isolates:
E. coli K. pneumoniae
(n = 18)(n = 10)
MIC50 MIC90 MIC50 MIC90
Amikacin2160.54
Ampicillin>256>256>256>256
Amoxicillin-clavulanate616816
Aztreonam>256>256>256>256
Cefepime>256>256>256>256
Cefotaxime>256>256>256>256
Cefoxitin212412
Ceftazidime32>256>256>256
Cefuroxime>256>256>256>256
Ciprofloxacin>32>32>32>32
Colistin0.00220.0641.5
Ertapenem0.01250.750.0640.5
Gentamicin1160.5>256
Imipenem0.1250.750.1250.25
Meropenem0.0940.1250.0471
Piperacillin-tazobactam0.75>2560.5>256
Tigecycline0.51.50.1251
Antibiotic susceptibility profiles of the bla CTX-M ESBL-positive E. coli and K. pneumoniae. As shown in Table 2, of the 38 ESBL-producing isolates, 30 (79 %) harbored blaCTX-M genes. Sequence analysis of these genes revealed that they were all blaCTX-M-15. Twenty-nine (96.7 %) of these, also harbored blaTEM genes simultaneously. A combination of blaCTX-M-15, blaTEM and blaSHV were found in 6 isolates; the distribution of the blaSHV was blaSHV-11 (2), blaSHV-12 (2) and blaSHV-112 (2). All 30 isolates positive for blaCTX-M carried insertion sequence blaIS upstream of the blaCTX-M-15 genes.
Table 2

Distribution of bla CTX-M β-lactamase genes among ESBL-producing Enterobacteriaceae isolates

Bacterial isolateNo. (%) of ESBL-positives (n = 38)No. (%) of isolates harboring bla genes:
bla CTX-M-15 bla TEM-1 bla SHV
(n = 30)(n = 29)(n = 6)
E. coli 21 (55.3)18 (60.0)17 (58.6)2 (33.3)
K. pneumoniae 12 (31.6)10 (33.3)9 (31.0)2 (33.3)
P. mirabilis 3 (7.9)2 (6.7)3 (10.4)0 (0)
M. morganii 1 (2.6)0 (0)0 (0)1 (16.7)
C. freundii 1 (2.6)0 (0)0 (0)1 (16.7)
Distribution of bla CTX-M β-lactamase genes among ESBL-producing Enterobacteriaceae isolates The ESBL E-test for ESBL production detected all the blaCTX-M, blaTEM and blaSHV-positive isolates confirmed by PCR. Testing both cefotaxime and ceftazidime was necessary for detection of CTX-M-positive isolates. As demonstrated in Table 1, the MIC90s of the third-generation cephalosporins were all >256 μg/ml. Our blaCTX-M-positive isolates, with or without SHV and TEM, were susceptible to amikacin, colistin, imipenem, meropenem and tigecycline. Three isolates (2 E. coli and 1 K. pneumoniae) were not inhibited at the cut-off breakpoint (0.5 μg/ml) of ertapenem but were susceptible to imipenem (MIC = 0.125 and 0.5 μg/ml) and meropenem (0.5 and 0.75 μg/ml). There was no specific distribution of the CTX-M-15-positive isolates among ethnic groups of the Yoruba race. Two E. coli and a Proteus spp. isolates were positive for ESBL but the genes encoding their production were not detected.

Clonal relatedness of the blaCTX-M-15 harboring isolates

The fingerprinting of the genomic DNA of the blaCTX-M-15-positive randomly selected isolates of E. coli and K. pneumoniae showed that the E. coli isolates were genetically heterogeneous, as the isolates did not fall within a particular cluster. On the other hand, there was about 98 % similarity with the K. pneumoniae isolates.

Discussion

The predominant genotype of the ESBL found in the clinical isolates of Enterobacteriaceae in this study was blaCTX-M-type genes with all being blaCTX-M-15; over 96 % of these 38 isolates also harbored a blaTEM β-lactamase gene. Five isolates co-harbored narrow-spectrum blaSHV-11 and other blaSHV genes. Our data demonstrate a very high prevalence of blaCTX-M type ESBL genes among the multidrug-resistant (MDR) isolates studied. This lends credence to the worldwide pandemic spread of the CTX-M β-lactamase enzyme, a phenomenon that has reached epidemic proportion among members of the family Enterobacteriaceae. The ESBL mediated by blaCTX-M type β-lactamase genes are undoubtedly the most widespread enzymes produced among members of this family. This assertion is predicated on the fact that over 79 % of our ESBL-producing isolates harbored blaCTX-M, the gene that mediates CTX-M enzyme production. Remarkably, all the CTX-M enzymes were CTX-M-15, making this type of β-lactamase the most common type detected in Enterobacteriaceae in this Lagos hospital. The dominance of blaCTX-M-15 β-lactamase genes in our snap surveillance study confirms what other workers had earlier reported in North America [15, 27, 28], Europe [29, 30], South America [31] the Middle East [23, 32] and Nigeria [16-20]. This ESBL gene has also been incriminated in community outbreaks of multidrug resistant (MDR) E. coli infections in some parts of the UK [30] and elsewhere [15]. The literature on the genetic characteristics of ESBLs in Nigeria and, indeed, Africa is sparse. The data emanating so far from Nigeria does not include the prevalence of the CTX-M ESBL in an in-patient setting. With this study we have demonstrated that the prevalence of Enterobacteriaceae isolates carrying genes that encode CTX-M-15 ESBL enzymes is at an unacceptable level with potential clinical and financial implications for the hospital. The clinical implication of this finding is that many patients infected by MDR Gram-negative bacteria stand the risk of treatment failure and cases of fatalities may increase. Thus, treatment of such infections assumes a great challenge to the clinician and the clinical microbiologists as treatment options are limited to very expensive and sometimes toxic drugs. Added to this burden is the fact that the location of the mobile genetic element, ISEcp1, a single copy insertion sequence responsible for mobilization of bla genes, was found upstream of the blaCTX-M genes. This has grave consequences as it might conceivably facilitate the spread of these genes among the Enterobacteriaceae within the hospital. Transfer of the blaCTX-M-15 genes to recipient E. coli J53 has been shown to be quite readily achievable. This suggests that resistance genes can easily move from one species to another with the possibility of easy interspecies transfer. One of the limitations of this study was that plasmids were not studied to determine if these genes were the same.

Conclusion

In conclusion, our study demonstrated an explosive emergence of isolates harboring blaCTX-M-15 gene mediating CTX-M-type ESBL production in invasive members of family Enterobacteriaceae. Immediate implementation of antibiotic stewardship and other preventive strategies are necessary to stem the tide of dangerous spread of MDR Enterobacteriaceae in this Lagos hospital.
  30 in total

1.  Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3.

Authors:  Laurent Poirel; Marek Gniadkowski; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

2.  Emergence of nosocomial New Delhi metallo-β-lactamase-1 (NDM-1)-producing Klebsiella pneumoniae in patients admitted to a tertiary care hospital in Kuwait.

Authors:  W Jamal; V O Rotimi; M John Albert; F Khodakhast; E E Udo; L Poirel
Journal:  Int J Antimicrob Agents       Date:  2011-11-22       Impact factor: 5.283

3.  Point-surveillance of antibiotic resistance in Enterobacteriaceae isolates from patients in a Lagos Teaching Hospital, Nigeria.

Authors:  Muhabat Adeola Raji; Wafaa Jamal; Omoh Ojemhen; Vincent O Rotimi
Journal:  J Infect Public Health       Date:  2013-06-17       Impact factor: 3.718

Review 4.  Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

Authors:  George H Talbot; John Bradley; John E Edwards; David Gilbert; Michael Scheld; John G Bartlett
Journal:  Clin Infect Dis       Date:  2005-01-25       Impact factor: 9.079

Review 5.  Antibiotic policies to control hospital-acquired infection.

Authors:  I M Gould
Journal:  J Antimicrob Chemother       Date:  2008-02-14       Impact factor: 5.790

6.  Sequence type ST131 and ST10 complex (ST617) predominant among CTX-M-15-producing Escherichia coli isolates from Nigeria.

Authors:  I Aibinu; T Odugbemi; W Koenig; B Ghebremedhin
Journal:  Clin Microbiol Infect       Date:  2011-12-22       Impact factor: 8.067

Review 7.  Hospital-acquired infections due to gram-negative bacteria.

Authors:  Anton Y Peleg; David C Hooper
Journal:  N Engl J Med       Date:  2010-05-13       Impact factor: 91.245

8.  ColE1-like plasmid pIP843 of Klebsiella pneumoniae encoding extended-spectrum beta-lactamase CTX-M-17.

Authors:  Van Cao; Thierry Lambert; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

9.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Authors:  N Woodford; M E Ward; M E Kaufmann; J Turton; E J Fagan; D James; A P Johnson; R Pike; M Warner; T Cheasty; A Pearson; S Harry; J B Leach; A Loughrey; J A Lowes; R E Warren; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

10.  First description of Escherichia coli producing CTX-M-15- extended spectrum beta lactamase (ESBL) in out-patients from south eastern Nigeria.

Authors:  Ifeanyichukwu R Iroha; Charles O Esimone; Sandra Neumann; Lennart Marlinghaus; Miriam Korte; Florian Szabados; Sören Gatermann; Martin Kaase
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-07-23       Impact factor: 3.944

View more
  5 in total

1.  Extended Spectrum Beta-Lactamase (ESBL)-producing bacteria isolated from hospital wastewaters, rivers and aquaculture sources in Nigeria.

Authors:  Olawale Olufemi Adelowo; Serena Caucci; Omowunmi Abosede Banjo; Ozioma Chinyere Nnanna; Eunice Olubunmi Awotipe; Florence Bosede Peters; Obasola Ezekiel Fagade; Thomas U Berendonk
Journal:  Environ Sci Pollut Res Int       Date:  2017-11-14       Impact factor: 4.223

2.  Very high prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in bacteriemic patients hospitalized in teaching hospitals in Bamako, Mali.

Authors:  Samba Adama Sangare; Emilie Rondinaud; Naouale Maataoui; Almoustapha Issiaka Maiga; Ibrehima Guindo; Aminata Maiga; Namory Camara; Oumar Agaly Dicko; Sounkalo Dao; Souleymane Diallo; Flabou Bougoudogo; Antoine Andremont; Ibrahim Izetiegouma Maiga; Laurence Armand-Lefevre
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240

Review 3.  Beta-lactamase resistance genes in Enterobacteriaceae from Nigeria.

Authors:  Babafela B Awosile; Michael Agbaje; Oluwawemimo Adebowale; Olugbenga Kehinde; Ezekiel Omoshaba
Journal:  Afr J Lab Med       Date:  2022-02-22

4.  Whole genome sequencing of extended-spectrum β-lactamase genes in Enterobacteriaceae isolates from Nigeria.

Authors:  Christiana Jesumirhewe; Burkhard Springer; Franz Allerberger; Werner Ruppitsch
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240

5.  Molecular detection and antibiotic resistance pattern of extended-spectrum beta-lactamase producing Escherichia coli in a Tertiary Hospital in Enugu, Nigeria.

Authors:  Ifeyinwa N Nwafia; Martin E Ohanu; Samuel O Ebede; Uchenna C Ozumba
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-12-12       Impact factor: 3.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.